Send to

Choose Destination
Respirology. 2015 Oct;20(7):1010-22. doi: 10.1111/resp.12569. Epub 2015 Jun 24.

Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers.

Hambly N1,2,3, Shimbori C1,2,3, Kolb M1,2,3.

Author information

Firestone Institute for Respiratory Health, Hamilton, ON, Canada.
St. Joseph's Healthcare, Hamilton, ON, Canada.
Department of Medicine, McMaster University Hamilton, Hamilton, ON, Canada.


Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic lung disease associated with high morbidity and poor survival. Characterized by substantial disease heterogeneity, the diagnostic considerations, clinical course and treatment response in individual patients can be variable. In the past decade, with the advent of high-throughput proteomic and genomic technologies, our understanding of the pathogenesis of IPF has greatly improved and has led to the recognition of novel treatment targets and numerous putative biomarkers. Molecular biomarkers with mechanistic plausibility are highly desired in IPF, where they have the potential to accelerate drug development, facilitate early detection in susceptible individuals, improve prognostic accuracy and inform treatment recommendations. Although the search for candidate biomarkers remains in its infancy, attractive targets such as MUC5B and MPP7 have already been validated in large cohorts and have demonstrated their potential to improve clinical predictors beyond that of routine clinical practices. The discovery and implementation of future biomarkers will face many challenges, but with strong collaborative efforts among scientists, clinicians and the industry the ultimate goal of personalized medicine may be realized.


biomarker; genetics; idiopathic pulmonary fibrosis

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center